PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology

Last updated: May 7, 2025
Sponsor: UNC Lineberger Comprehensive Cancer Center
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Kidney Cancer

Renal Cell Carcinoma

Cancer/tumors

Treatment

Survey Questionnaire

Clinical Study ID

NCT05592665
LCCC2126
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to investigate how collecting information about treatment-related side effects directly from patients can help manage the side effects associated with certain oral chemotherapies. This study is specifically investigating this approach in patients taking oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC).

Participants in this study will receive a survey via email or telephone once a week while receiving treatment with a VEGFR TKI. The survey will ask about symptoms such as nausea or fatigue and overall quality of life. This survey should take no more than 15 minutes to complete.

The survey will be sent directly to the oncology care team. Participants will receive a follow-up phone call or message from the team when participants have new or worsening symptoms. The participants will continue to receive surveys for as long as they are receiving a VEGF TKI treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients aged 18 years or older

  • Histologically confirmed renal cell carcinoma requiring treatment with VEGF TKI.

  • Patients may be receiving other concurrent cancer-directed therapy such as immunecheckpoint inhibitors.

  • English or Spanish speaking

  • Ability to complete PRO surveys (i.e. ability to read/write or access to telephoneor internet)

  • Willing and able to meet all study requirements

Exclusion

Exclusion Criteria:

All subjects meeting any of the exclusion criteria at baseline will be excluded from study participation.

• Inability for any reason to complete PRO surveys

Study Design

Total Participants: 42
Treatment Group(s): 1
Primary Treatment: Survey Questionnaire
Phase:
Study Start date:
March 18, 2022
Estimated Completion Date:
January 16, 2031

Connect with a study center

  • Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina 27514
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.